Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients
MetadataShow full item record
AuthorGutiérrez Bautista, Juan Francisco; Rodríguez Nicolás, Antonio; Rosales Castillo, Antonio; López Ruz, Miguel Ángel; Martín Casares, Antonia María; Fernández Rubiales, Alonso; Anderson, Per; Garrido Torres-Puchol, Federico; Ruiz-Cabello Osuna, Francisco; López Nevot, Miguel Ángel
Juan Francisco Gutiérrez-Bautista... [et al.]. Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients, Journal of Microbiology, Immunology and Infection, Volume 55, Issue 3, 2022, Pages 421-427, ISSN 1684-1182, [https://doi.org/10.1016/j.jmii.2021.08.009]
SponsorshipInstituto de Salud Carlos III - FEDER funds (European Union) PI 16/00752; Junta de Andalucia CTS-143 C-0013-2018; RAFER S.L.
Background: Human leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules present, some will be more or less effective in controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may be involved in the protection or susceptibility to COVID-19. Methods: We studied the polymorphisms in HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one of the largest HLA-typed patient cohort to date. Results: Our results show that there is no relationship between HLA polymorphisms or haplotypes and susceptibility or protection to COVID-19. Conclusion: Our results may contribute to resolve the contradictory data on the role of HLA polymorphisms in COVID-19 infection.